Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s): MEDXF

Healthcare

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

TSX:MDP - Post by User

Medexus Pharmaceuticals Inc > October 16, 2023

<< Previous

Bullboard Posts

Next >>

Comment by existaboon Jun 22, 2023 4:15pm

113 Views

Post# 35509944

RE:RE:October 16, 2023

On top of great results and financial strength, broker are going to look for action on M&A and ask their analyst to write it up. We need new buyer to push the 50 day moving aver. back up past the 200.

<< Previous

Bullboard Posts

Next >>

First Helium advances winter drilling program with Leduc Anomaly test well